DUBLIN–(BUSINESS WIRE)–The “HER2 Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change” report has been added to ResearchAndMarkets.com’s offering.
The global HER2 inhibitors market is expected to decline from $6.21 billion in 2019 to $6.07 billion in 2020 at a compound annual growth rate (CAGR) of -2.19%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of several activities resulting in operational challenges.
The market is then expected to recover and reach $8.29 billion in 2023 at a CAGR of 10.96%.
Major players in the HER2 inhibitors market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Boehringer-Ingelheim, Mylan and Biocon.
The HER2 inhibitors market consists of sales of HER2 inhibitors and related services by entities (organizations, sole traders, and partnerships) that manufacture HER2 inhibitors. Human epidermal growth factor receptor (HER2) inhibitors slow down or stop cell growth thus reducing the risk for cancer growth.
The HER2 inhibitor market covered in this report is segmented by treatment into monotherapy; combination therapy and by end user into squamous cell carcinoma; adenocarcinoma; large cell carcinoma; breast cancer; others.
High costs associated with the HER-2 inhibitors treatment is a major issue faced by citizens of many countries. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding.
In less wealthy countries, the lack of cost-effective therapies for cancer has influenced the health conditions of the population and has led to a low average life expectancy. Trastuzumab, a licensed HER2 inhibitor, has been the most expensive systemic cancer therapy procedure at a variety of disease sites.
In 2019, the cost of trastuzumab in India ranged from $774.6 to $841.35 per 440 mg vial. In patients with HER 2 positive early breast cancer, nearly 18 cycles of therapy based on trastuzumab are needed that further charge more than $1,335.52 in India. Therefore, the high cost of HER2 inhibitors is expected to hinder the growth of the HER2 inhibitors market.
Biotechnology companies are focusing on acquiring or partnering with biopharmaceutical companies to develop and promote the HER-2 inhibitors market. There have been several partnerships in recent years which help these companies to increase their HER-2 inhibitors portfolio, enhance their revenues and share the costs.
The rise in the number of breast cancer cases across the globe is likely to contribute to the growth of the HER-2 inhibitors market during the forecast period. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. As of January 2020, there were more than 3.5 million women with a history of breast cancer in the US.
Key Topics Covered:
1. Executive Summary
2. HER2 Inhibitors Market Characteristics
3. HER2 Inhibitors Market Size And Growth
3.1. Global HER2 Inhibitors Historic Market, 2015 – 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global HER2 Inhibitors Forecast Market, 2019 – 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market
4. HER2 Inhibitors Market Segmentation
4.1. Global HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
- Monotherapy
- Combination Therapy
4.2. Global HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
- Squamous Cell Carcinoma
- Adenocarcinoma
- Large Cell Carcinoma
- Breast Cancer
- Others
5. HER2 Inhibitors Market Regional And Country Analysis
5.1. Global HER2 Inhibitors Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global HER2 Inhibitors Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Puma Biotechnology Inc.
- Boehringer-Ingelheim
- Mylan
- Biocon
For more information about this report visit https://www.researchandmarkets.com/r/tnl76p
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900